1. Home
  2. DRCT vs PHGE Comparison

DRCT vs PHGE Comparison

Compare DRCT & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Direct Digital Holdings Inc.

DRCT

Direct Digital Holdings Inc.

HOLD

Current Price

$0.76

Market Cap

8.9M

Sector

Technology

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$4.68

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRCT
PHGE
Founded
2018
2015
Country
United States
United States
Employees
N/A
57
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.9M
9.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
DRCT
PHGE
Price
$0.76
$4.68
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$330.00
N/A
AVG Volume (30 Days)
113.3K
65.7K
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$62,288,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$58.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$0.25
52 Week High
$6.04
$8.50

Technical Indicators

Market Signals
Indicator
DRCT
PHGE
Relative Strength Index (RSI) 34.68 42.86
Support Level $0.50 $4.00
Resistance Level $0.79 $5.99
Average True Range (ATR) 0.08 0.76
MACD -0.00 -0.18
Stochastic Oscillator 13.86 4.50

Price Performance

Historical Comparison
DRCT
PHGE

About DRCT Direct Digital Holdings Inc.

Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: